How Does Semaglutide Work? The Mechanism, Plainly

Semaglutide works by imitating a hormone your body already produces every time you eat.

That is the whole mechanism in one sentence, and almost everything else — why it reduces appetite, why the side effects are what they are, why it is injected rather than swallowed, why the dose steps up slowly, and why the weight comes back when you stop — follows from it. This page walks through the chain in order, because understanding one link explains several things people find surprising.

The Hormone It Copies

After a meal, cells in your gut release GLP-1 — glucagon-like peptide-1. It is a signal that food has arrived, and it does several things at once, which is why one drug produces several effects¹.

Native GLP-1 is useless as a medicine for one reason: an enzyme in your blood clears it within minutes. Your body wants that signal to be brief. A drug needs it to last.

This one engineered molecule is sold under three brand names: Ozempic for type 2 diabetes, Wegovy for weight management, and Rybelsus as a daily oral tablet. The mechanism on this page is the same in all three — what differs is the dose and the delivery. If you are handling a compounded vial rather than a branded pen, the semaglutide dosage calculator and the reconstitution calculator do the milligrams-to-units arithmetic that the pens do for you.

Semaglutide is engineered GLP-1 that survives. It is a chain of 31 amino acids based on the human hormone, with two modifications: substitutions that resist the enzyme that would break it down, and a fatty-acid chain attached so the molecule binds to albumin in the blood and is released slowly². That second modification — acylation — is why a once-weekly injection is possible at all. Almost the entire engineering effort behind the drug went into making a brief signal into a persistent one.

The Four Things It Does

Once semaglutide is activating the GLP-1 receptor continuously rather than in post-meal bursts, four effects follow¹.

It slows gastric emptying. Food leaves your stomach more slowly, so you feel full sooner and stay full longer. This is the effect people notice first and describe as "I just forget to eat."

It acts on appetite regulation in the brain. The GLP-1 receptor is present in brain regions involved in appetite and reward, and this central action is a large part of why the drug reduces how much people want to eat, not merely how much they can.

It increases insulin release when glucose is high — and importantly, in a glucose-dependent way, meaning the effect scales with blood sugar rather than firing regardless. That is why this class is used in type 2 diabetes and why it behaves differently from insulin itself.

It suppresses glucagon, the hormone that tells the liver to release stored glucose.

The first two drive the weight loss. The second two drive the glycemic effect. One receptor, four consequences.

Why the Side Effects Are What They Are

Here the mechanism pays off, because the common side effects are not a mysterious add-on — they are the same actions, felt differently.

Nausea, vomiting, early fullness, constipation and diarrhea are the dose-limiting problems for this drug class, and they follow directly from slowed gastric emptying and altered gut signaling. The thing that makes the drug work is the thing that makes people feel sick, which is why side effects tend to track dose and effect together rather than being independent of them.

That also explains the schedule. The approved products titrate slowly — a low starting dose held for weeks, stepping up only if tolerated — precisely so tolerance can develop. The trial results everyone quotes were produced under that titration³⁴, not by skipping it, and the standard response to poor tolerance is to slow the ladder rather than abandon the drug. We cover the arithmetic version of this for the sister molecule in tirzepatide dosage.

Why It Is Injected

A reasonable question with a chemical answer: semaglutide is a peptide, and your digestive system exists to break peptides apart.

An oral version does exist and is approved, which proves it is possible — but it required co-formulating the drug with an absorption enhancer whose only job is to help it survive and cross, and even then only a small fraction of each dose reaches the bloodstream, which is why the oral dosing instructions are strict about timing and water. We take that apart in oral peptides for weight loss, including the development that reframes the whole question: the newest oral drug for this target works precisely because it is not a peptide.

Why the Weight Comes Back

This is the part of the mechanism that gets least attention and explains the most.

Semaglutide does not change your body's set point permanently or repair anything. It supplies a signal, continuously, for as long as you take it. Stop the injections and the signal stops — appetite regulation returns to where it was, gastric emptying returns to normal, and the conditions that produced the original weight are back in place.

That is not a failure of the drug; it is what the mechanism implies. It is also why "how do I come off it" is a real clinical question rather than an afterthought, and why maintenance dosing is an open area — covered in microdosing tirzepatide, where the honest finding is that no trial has tested a maintenance protocol.

What You Lose, and What That Means

A mechanism that reduces intake produces weight loss from whatever the body draws on, and a substantial share of that is lean tissue rather than fat. This is the most under-discussed fact in the category and it is a direct consequence of how the drug works — it reduces calories consumed; it does not direct where the deficit is taken from.

The numbers are in semaglutide, tirzepatide and muscle loss. The mitigation is unglamorous and well supported: resistance training and adequate protein alongside the drug, not instead of it — peptides for weight loss and muscle gain.

What It Does Not Do

Worth being explicit, because the mechanism gets stretched in both directions.

It does not speed up your metabolism. The weight loss comes from reduced intake, not increased expenditure. If anything, losing weight tends to reduce energy expenditure, which is part of why maintenance is its own problem.

It does not target fat specifically. The receptor is not on your fat cells directing them to release; it is producing a calorie deficit, and the body decides what to draw on.

It does not treat the cause of anything. It supplies a signal for as long as it is present. That is a description of how it works rather than a criticism — the same is true of many long-term medicines — but it does mean framing it as a course of treatment with an end date misunderstands the mechanism.

It is not the same as the other peptides sold alongside it. Semaglutide's evidence was generated by testing semaglutide. Sharing a chemical class with BPC-157 or sermorelin transfers nothing, which is the argument of is Ozempic a peptide and what are peptides good for.

Why the Same Receptor Produces Different Drugs

A question that follows naturally: if tirzepatide also works on GLP-1, why is it different?

Because it does not only work on GLP-1. Tirzepatide is a 39-amino-acid peptide that activates GIP as well, which is why it is called a dual agonist — and that difference is the accepted explanation for why it outperformed semaglutide when the two were compared head to head⁵. Retatrutide adds a third receptor and remains investigational.

So the family is not a set of interchangeable versions of one drug. Each one activates a different combination of receptors, and those combinations produce measurably different results. We compare the two approved ones in tirzepatide vs semaglutide and the investigational one in retatrutide vs tirzepatide.

What the Evidence Behind It Looks Like

Worth stating because it is unusual in this field. Semaglutide's weight-loss use rests on the STEP program — randomized, placebo-controlled trials, with STEP 1 establishing substantial sustained weight loss over 68 weeks³ across a broader trial series⁴. It has also been compared directly against tirzepatide in a randomized head-to-head⁵, which is rare enough in this space to be worth noticing.

That evidence belongs to semaglutide specifically. It does not transfer to other peptides that happen to share a chemical class — a point we make at length in is Ozempic a peptide.

The Product You Buy Is Not Always the Product Tested

The trials studied the approved, manufactured product. A compounded version — same molecule, made by a compounding pharmacy rather than the manufacturer — is a different product whose regulatory position has moved more than once. See is compounded semaglutide or tirzepatide still legal and the peptide FDA status tracker.

Prices in that market frequently describe a term rather than a rate. SkinnyRx publishes four terms per product — injectable semaglutide at $349 monthly, $299 on four months, $249 on six and $199 only on twelve — while every tile on the site advertises "As low as $199/mo". LaSara charges $299 for one month on its live pages while its marketing page still says "starting at $179". Care Bare Rx names four GLP-1 products and publishes a price for none of them. HealthRX publishes the whole ladder with prepay marked optional, which is what a fair page looks like.

Board: best semaglutide providers, with figures in the price transparency index and everything on the rankings index.

Bottom Line

Semaglutide is engineered GLP-1 — a 31-amino-acid copy of a gut hormone you release after every meal, modified to resist the enzyme that would clear it and acylated so it binds albumin and lasts a week².

Activating that receptor continuously slows gastric emptying, acts on appetite regulation in the brain, increases glucose-dependent insulin release and suppresses glucagon¹. The first two produce the weight loss; the second two produce the glycemic effect.

Four things follow that people find surprising and shouldn't:

• •The side effects are the mechanism. Nausea and early fullness come from the same slowed gastric emptying that makes it work, which is why the dose titrates slowly.
• •It is injected because it is a peptide, and digestion dismantles peptides — the approved oral version needed a purpose-built absorption enhancer to exist.
• •The weight returns when you stop, because the drug supplies a signal rather than changing anything permanently.
• •Part of what you lose is lean tissue, because reducing intake does not direct where the deficit comes from.

For the comparison with the other molecule in this class, see tirzepatide vs semaglutide. This page is educational and not medical advice.